| Identification | Back Directory | [Name]
2-Pyridinamine, N-cyclohexyl-4-[1-(1-piperazinyl)-2,6-naphthyridin-3-yl]- | [CAS]
1071135-06-2 | [Synonyms]
N-Cyclohexyl-4-[1-(1-piperazinyl)-2,6-naphthyridin-3-yl]-2-pyridinamine
2-Pyridinamine, N-cyclohexyl-4-[1-(1-piperazinyl)-2,6-naphthyridin-3-yl]-
NCyclohexyl4[1(1piperazinyl)2,6naphthyridin3yl]2pyridinamine,N Cyclohexyl 4 [1 (1 piperazinyl) 2,6 naphthyridin 3 yl] 2 pyridinamine | [Molecular Formula]
C23H28N6 | [MOL File]
1071135-06-2.mol | [Molecular Weight]
388.51 |
| Chemical Properties | Back Directory | [Boiling point ]
654.9±55.0 °C(Predicted) | [density ]
1.218±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
8.43±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
PKC/PKD-IN-1 (Compound 13C) is an orally active dual protein kinase C/D (PKC/PKD) inhibitor with an IC50 value of 0.6 nM for PKD1. PKC/PKD-IN-1 can attenuate high-salt diet-induced cardiac hypertrophy and can be used in the study of heart failure[1]. | [in vivo]
PKC/PKD-IN-1 (Compound 13C) (5-50 mg/kg; p.o.; once daily for 14 days) , in Dahl salt-sensitive (DSS) rats, can attenuate high-salt diet-induced cardiac hypertrophy at a dose of 50 mg/kg[1]. | [IC 50]
PKD1: 0.6 nM (IC50) | [References]
[1] Meredith EL, et al. Identification of orally available naphthyridine protein kinase D inhibitors. J Med Chem. 2010;53(15):5400-5421. DOI:10.1021/jm100075z |
|
|